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Abstract
Introduction: Hemojuvelin (Hjv) is a key component of the signaling cascade that regulates liver hepcidin (Hamp)
expression. The purpose of this study was to determine Hjv protein levels in mice and rats subjected to iron overload and
iron deficiency.
Methods: C57BL/6 mice were injected with iron (200 mg/kg); iron deficiency was induced by feeding of an iron-deficient
diet, or by repeated phlebotomies. Erythropoietin (EPO)-treated mice were administered recombinant EPO at 50 U/mouse.
Wistar rats were injected with iron (1200 mg/kg), or fed an iron-deficient diet. Hjv protein was determined by
immunoblotting, liver samples from Hjv2/2 mice were used as negative controls. Mouse plasma Hjv content was
determined by a commercial ELISA kit.
Results: Liver crude membrane fraction from both mice and rats displayed a major Hjv-specific band at 35 kDa, and a
weaker band of 20 kDa. In mice, the intensity of these bands was not changed following iron injection, repeated bleeding,
low iron diet or EPO administration. No change in liver crude membrane Hjv protein was observed in iron-treated or iron-
deficient rats. ELISA assay for mouse plasma Hjv did not show significant difference between Hjv+/+ and Hjv2/2 mice. Liver
Hamp mRNA, Bmp6 mRNA and Id1 mRNA displayed the expected response to iron overload and iron deficiency. EPO
treatment decreased Id1 mRNA, suggesting possible participation of the bone morphogenetic protein pathway in EPO-
mediated downregulation of Hamp mRNA.
Discussion: Since no differences between Hjv protein levels were found following various experimental manipulations of
body iron status, the results indicate that, in vivo, substantial changes in Hamp mRNA can occur without noticeable changes
of membrane hemojuvelin content. Therefore, modulation of hemojuvelin protein content apparently does not represent
the limiting step in the control of Hamp gene expression.
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Introduction
Humans lack a regulated pathway for iron excretion, and body
iron stores are therefore determined solely at the level of iron
uptake in the small intestine. Mammalian iron absorption is
primarily controlled by the hepatocyte-derived peptide hepcidin,
encoded by the HAMP gene. Hepcidin regulates ferroportin-
mediated iron export from enterocytes and macrophages, and thus
determines dietary iron uptake, as well as the amount of iron
available for erythropoiesis [1,2,3,4].
Hepcidin expression is in turn regulated by three key factors:
body iron stores, inflammation, and erythropoietic activity. In
mice, iron overload or inflammation increase Hamp mRNA, while
iron deficiency or accelerated erythropoiesis decrease it. At
present, the signaling pathway responsible for inflammation-
mediated activation of Hamp gene transcription has to a significant
extent been elucidated, and substantial progress has been made
towards the understanding of Hamp gene regulation by iron
overload and iron deficiency. On the other hand, the mechanisms
responsible for Hamp mRNA downregulation by accelerated
erythropoiesis are still largely unknown [2,3].
An important part of the processes related to the transcriptional
control of hepcidin biosynthesis occurs at the hepatocyte plasma
membrane. The key signaling pathway which regulates Hamp gene
expression in response to liver iron stores is the bone morphoge-
netic protein/hemojuvelin (Bmp/Hjv) pathway [5,6,7], whose
central component is the glycosylphosphatidylinositol (GPI)-
anchored protein hemojuvelin (Hjv), encoded by the Hfe2 gene
[8]. The first known step in the signaling cascade which ultimately
leads to hepcidin secretion by the hepatocyte is the transcriptional
activation of bone morphogenetic protein 6 (Bmp6) expression [9].
Bmp6, probably a product of non-parenchymal liver cells [10],
subsequently binds to Hjv at the extracellular side of the
hepatocyte membrane, resulting in effective interaction of Bmp6
with its transmembrane receptors. Hjv thus serves as a Bmp6
coreceptor. Activation of Bmp receptors then results in intracel-
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tional activation of hepcidin synthesis. The importance of Bmp6
and hemojuvelin in hepcidin expression is evident from the fact
that disruption of mouse Bmp6 [6,7] or Hfe2 [11,12] genes results
in severe hemochromatosis, which is in terms of tissue iron
overload similar to hemochromatosis caused by disruption of the
hepcidin gene itself. At present, the Bmp/Hjv pathway is therefore
regarded as the main pathway which controls Hamp expression in
response to liver iron levels. In addition to Hamp, the Bmp/Hjv
pathway also activates transcription of several other genes, of
which the Id1 gene is often used as a convenient marker of Bmp6-
dependent signaling [9].
A less severe form of hemochromatosis, associated with a less
dramatic decrease in hepcidin expression, is caused by disrupted
synthesis of two other membrane proteins: transferrin receptor 2
(Tfr2) [13] and the Hfe protein [14]. The exact role of these two
proteins in hepcidin gene regulation is unknown, but they very
probably participate in the sensing of plasma iron levels [15].
The most recently identified hepatocyte membrane protein
involved in iron homeostasis regulation is the serine protease
matriptase-2, encoded by the Tmprss6 gene [16,17,18]. In contrast
to Bmp6, Hjv, Tfr2 and Hfe, which increase hepcidin transcrip-
tion, matriptase-2 is a negative regulator of hepcidin. Mutations in
TMPRSS6 cause inappropriately high hepcidin synthesis, resulting
in iron-refractory iron deficiency anemia in humans. Mice with
disrupted function of the matriptase-2 protein display high Hamp
mRNA in the face of decreased liver iron stores and iron-deficient
erythropoiesis [16,18,19], as well as a blunted response to
erythropoietin (EPO) administration [20,21]. Evidently, functional
matriptase-2 is indispensable in order to adequately lower
hepcidin transcription in response to physiological stimuli.
Since matriptase-2 is a membrane-bound serine protease, it very
probably acts by cleaving an essential component of the hepcidin-
regulatory pathway. By extensive in vitro experiments, Silvestri et al.
have identified membrane hemojuvelin as the main target of
matriptase-2 proteolytic activity [22]. By cleaving hemojuvelin,
matriptase-2 is proposed to remove a crucial constituent of the
Bmp/Hjv pathway from the membrane, and thus decrease Hamp
expression. This concept has been further strengthened by studies
on double mutant mice lacking both matriptase-2 and hemojuvelin
[23,24], which display a phenotype similar to hemojuvelin-mutant
mice, as well as by the demonstration that, in cultured hepatocytes,
hypoxia increases matriptase-2 expression and decreases mem-
brane Hjv protein [25]. Recently, it has been also reported that
iron-deficient diet increases matriptase-2 protein in rats [10].
Based on all these data, the emerging model of Hamp gene
regulation by iron deficiency or hypoxia links increased matrip-
tase-2 enzymatic activity to a decrease of Hjv protein at the
hepatocyte plasma membrane [4,10,25].
Despite the fact that hemojuvelin represents an important
component in the regulation of hepcidin expression, there is
comparatively little information on liver hemojuvelin protein
content in vivo. Particularly, reliable data from mouse models are
lacking, mainly because most antibodies detect false positive bands
on immunoblots [23]. Recently, we have used mice with targeted
disruption of the hemojuvelin gene (Hjv2/2 mice) to identify Hjv-
specific bands on immunoblots, and to optimize conditions for
hemojuvelin detection with a commercial antibody [26]. The
primary aim of the present study was to determine hemojuvelin
expression in states of altered iron homeostasis. The obtained
results show that hemojuvelin protein levels were not altered by
iron deficiency or iron overload, indicating that substantial
variation in Hamp gene transcription can occur without noticeable
changes in membrane hemojuvelin content.
Results
Manipulation of iron levels does not change membrane
hemojuvelin content in mice
Immunobloting of mouse Hjv is generally difficult due to the
presence of non-specific bands [20,23]. Therefore, to identify
hemojuvelin-specific bands on immunoblots, we have previously
used whole liver lysates from Hjv2/2 mice as negative controls
[26]. This approach enabled selection of a suitable commercial
antibody (AF3634), which, under reducing conditions, detects two
hemojuvelin-specific bands at approximately 35 and 20 kDa
(Fig. 1). These bands very probably represent two components
of Hjv heterodimer, which forms subsequently to autoproteolytic
cleavage of the full-length Hjv monomer [27,28]. Detection of the
35 kDa band was highly reproducible; on the other hand, the
signal from the 20 kDa band was weaker and its relative intensity
varied with the individual batch of the antibody used.
Comparison of hemojuvelin-specific bands in whole liver
homogenates from C57BL/6 mice subjected to iron overload or
iron deficiency showed no difference in band intensity between
control animals and treated animals (Fig. 1), despite large
differences in liver iron content (Table 1) and Hamp mRNA levels
(Fig. 2). These results indicate that total liver Hjv content does not
change following manipulation of liver iron levels.
Since hemojuvelin exists in both soluble and membrane-bound
forms [27], and since the Bmp6-dependent signaling is postulated
to depend on membrane-bound hemojuvelin, we next determined
the Hjv protein content in crude membrane fractions obtained by
ultracentrifugation. The Hjv signal from the crude membrane
fraction was generally stronger than the signal from whole liver
homogenate, and an additional weak band at 50 kDa, probably
representing the uncleaved membrane-bound Hjv monomer,
could be detected in some blots (Fig. 3A). Both the 35 kDa and
20 kDa Hjv-specific bands were readily visualized by another
antibody (AF3720) from the same company (Fig. 3B). Comparison
of samples from control mice and treated mice showed no
significant change in optical density of the major 35 kDa band
(Fig. 3C), indicating that membrane Hjv is not significantly altered
by iron overload or iron deficiency. To confirm that the
manipulation of iron levels does not produce any artificial bands
Figure 1. Hemojuvelin protein in mouse whole liver homoge-
nates. C: Control, Bl: Bleeding (0.6 ml of blood once weekly for 3
weeks), Fe: Iron injection (200 mg/kg), KO: Hjv2/2 mice. 80 mgo f
protein was loaded per lane. Arrows indicate Hjv-specific bands. Gapdh
was used as loading control. Primary anti-Hjv antibody: AF3634.
doi:10.1371/journal.pone.0037391.g001
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similar experimental treatment (iron administration, bleeding, and
EPO administration). No additional bands were observed (Figure
S1).
Hjv is attached to the plasma membrane by a GPI anchor
[27,28]. We have previously demonstrated that cleavage of the
GPI-binding enhances the signal from the 35 kDa band, and, in
addition, enables reproducible detection of the putative 50 kDa
monomer [26]. Therefore, in an additional experiment, liver
crude membrane fraction samples were treated with phosphati-
dylinositol-specific phospholipase C (Pi-PLC). This treatment
resulted in the release into the supernatant of two hemojuvelin-
specific bands: a major band of 35 kDa, and a weaker band of
50 kDa (Fig. 4A). As noted previously [26], the intensity of the
20 kDa band strongly decreased after Pi-PLC treatment. No
changes in the intensities of the 35 kDa band were apparent after
iron overload, iron depletion, bleeding or erythropoietin admin-
istration (Fig. 4B).
It has previously been reported that the amount of Hjv present
in the plasma membrane is relatively low compared to total
membrane Hjv protein [10]. Therefore, as an attempt to quantify
possible changes in plasma membrane Hjv, an additional set of
samples was prepared using a commercial plasma membrane
protein extraction kit. Total yield from a 150 mg piece of liver was
about 90 mg of protein enriched in plasma membrane fraction.
Immunoblotting of the liver plasma membrane fraction from iron-
overloaded and iron-deficient mice did not show any marked
differences between the samples (Fig. 5).
Manipulation of iron levels does not change membrane
hemojuvelin content in rats
Since the mature mouse Hjv protein shares more than 95%
amino acid identity with rat Hjv protein, it was of interest to
determine whether the anti-mouse Hjv antibodies could also be
usedtodetermineHjvproteinlevelsinrats.AscanbeseeninFig.6A
and B, both antibodies detected a band around 35 kDa in rat liver
crude membrane preparations, and a much weaker band at about
20 kDa. Under non-reducing conditions, the antibody detected a
single band of about 50 kDa (results not shown), which is in
agreement with the proposed composition of the Hjv heterodimer.
Treatment of Wistar rats with iron-dextran increased liver Hamp
mRNA levels to approximately 230%, while feeding of an iron
deficient diet decreased Hamp mRNA expression to less than 1%
(results not shown). Liver and plasma iron content significantly
decreased after feeding of an iron-deficient diet (Table 2). None of
the treatments significantly changed the intensity of the major
35 kDa band (Fig. 6C), confirming the recent observation that iron
deficiency does not influence rat liver total membrane Hjv protein
levels [10]. Overall, the immunoblotting experiments did not
demonstrate any substantial changes in liver hemojuvelin protein
content after manipulation of liver iron levels.
Iron deficiency does not result in detectable changes of
mouse plasma hemojuvelin
Soluble Hjv has been postulated to function as a negative
regulator of Hamp gene expression [27]. According to this concept,
soluble Hjv levels would be expected to increase in iron deficiency.
We therefore attempted to detect soluble Hjv by immunoblot, in
both whole and albumin-depleted plasma, as well as by a
commercially available ELISA kit. By immunoblotting of mouse
plasma, no differences were detected between animals fed normal
diet or iron-deficient diet for two months, despite a marked
decrease of liver Hamp mRNA in the latter (Fig. 7A). Similar
results were obtained in rats (results not shown). No Hjv-specific
band could be identified. Removal of the majority of albumin and
IgG from mouse plasma samples by an immunoaffinity depletion
kit enhanced the visualization of less abundant proteins; however,
comparison of samples from Hjv+/+ and Hjv2/2 mice again did
not detect any Hjv-specific bands (Fig. 7B). In both untreated and
albumin-depleted plasma, a strong non-specific band was apparent
at about 50 kDa.
Next, it was attempted to quantify plasma Hjv by a commercial
mouse Hjv ELISA kit. Although the assay generated a linear
calibration curve (y=8.7291x20.3426, R
2=0.9955), and the
obtained values were well within the calibration curve range, no
significant difference was seen between three pairs of plasma from
mice fed control diet or iron-deficient diet (Fig. 7C). Intriguingly,
comparison of five pairs of plasma samples from Hjv+/+ and
Hjv2/2 mice did not show any difference between the two groups
(Fig. 7C), despite an almost complete absence of Hjv mRNA in the
liver, muscle and heart of Hjv2/2 animals [11].
Erythropoietin treatment influences Bmp-dependent
signaling
To confirm the effect of the various experimental treatments
on iron homeostasis, liver Hamp mRNA levels were determined
by real-time PCR. As expected, iron treatment increased liver
Hamp expression, while feeding of an iron-deficient diet, repeated
bleeding or administration of erythropoietin dramatically
decreased Hamp mRNA content (Fig. 2). Iron treatment
Table 1. Effect of experimental protocols on iron status in mice.
Treatment Hemoglobin Hematocrit MCV Liver Iron Plasma Iron
g/l % fl mg/g wet wt. mmol/l
Control 149.764.7 46.262.5 4561 35.7610.0 22.268.9
Iron 149.862.0 47,561.1 4661 21656186 75.565.5 *
EPO 170.364.9 * 51.961.3 * 4761 25.762.7 * 6.166.8 *
Control diet 145.865.0 40.261.1 4461 82.1620.7 22.063.3
Low iron diet 144.665.2 41.061.4 4262 35.2619.6 * 10.762.1 *
Bleeding 63610 19633 7 611 4 66* 8 . 2 61.1 *
Iron was administered to male C57BL/6 mice as iron polyisomaltosate at 200 mg/kg, erythropoietin (EPO) was injected at 50 U/mouse on days 1–4, mice were sacrificed
on day 5. Low iron diet was fed to female C57BL/6 mice for four weeks after weaning, bleeding was performed once weekly (0.6 ml of blood) by retrobulbar puncture in
halothane anesthesia for four weeks. Asterisk denotes significant difference from controls (p,0.05, n$4).
doi:10.1371/journal.pone.0037391.t001
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Tmprss6 mRNA was unchanged by manipulation of hepatic iron
(Fig. 2).
The effect of the various treatments on Bmp-dependent
signaling was examined by monitoring hepatic Id1 mRNA levels.
Id1 is a well-recognized target of Bmp6 signaling [9], and the
determination of Id1 mRNA is in some cases more sensitive [29]
than the determination of phosphorylated Smad proteins, which is
traditionally [5] used for the monitoring of Bmp signaling
pathway. As expected, iron administration markedly increased
hepatic Id1 mRNA levels, while iron-deficient diet or repeated
bleeding resulted in a statistically significant decrease. Interesting-
ly, EPO treatment also decreased liver Id1 mRNA content (Fig. 2),
suggesting that the the Bmp/Hjv pathway could participate in the
well-documented downregulation of Hamp gene expression by
accelerated erythropoiesis. Liver Id1 mRNA levels were slightly
decreased in Hjv2/2 mice; however, in contrast to results
described in Bmp62/2 mice [7], the decrease did not reach
statistical significance, indicating that Id1 gene transcription is less
sensitive to the loss of Hjv than Hamp gene transcription.
Figure 2. Effect of iron status on mouse liver Hamp, Bmp6,
Tmprss6 and Id1 mRNA. Hamp, Bmp6, Tmprss6 and Id1 mRNA was
determined by real-time PCR and expressed relative to b-actin mRNA. C:
Control, Fe: Iron injection (200 mg/kg), ID: Iron-deficient diet, Bl:
Bleeding (0.6 ml of blood once weekly for 3 weeks), Epo: Erythropoietin
(50 U/day) administration for 4 days, WT: Hjv+/+ mice, KO: Hjv2/2
mice. Asterisks indicate statistically significant difference (n=4, p,0.05).
doi:10.1371/journal.pone.0037391.g002
Figure 3. Effect of iron status on mouse liver membrane
hemojuvelin. Immunoblots of Hjv protein in liver crude membrane
fractions. Panel A: Detection with primary anti-Hjv antibody AF3634.
Panel B: Identical samples detected with primary anti-Hjv antibody
AF3720. Panel C: Densitometric quantification of the 35 kDa Hjv band.
C: Control, Fe: Iron injection (200 mg/kg), Bl: Bleeding (0.6 ml of blood
once weekly for 3 weeks), ID: Iron-deficient diet, Epo: Erythropoietin
(50 U/day) administration for 4 days, WT: Hjv+/+ mice, KO: Hjv2/2
mice. 60 mg of protein was loaded per lane. Arrows indicate Hjv-specific
bands. Connexin 43 was used as loading control. For densitometry, the
optical density of control samples was set at 100%, n=4.
doi:10.1371/journal.pone.0037391.g003
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Although EPO administration is known to decrease Hamp
expression [30], the exact mechanism by which accelerated
erythropoiesis influences Hamp transcription is still unclear
[1,2,3]. It has been proposed that the EPO-induced decrease of
plasma iron could be an important contributing factor [31]. To
confirm the reported effect of EPO on iron metabolism [31], we
examined plasma iron content and liver non-heme iron content
after four days of EPO treatment. As can be seen in Table 1,
daily administration of a high dose (50 U) of EPO markedly
decreased plasma iron content, and, in addition, also caused a
decrease in liver iron content. These data confirm that the
traditional experimental protocol (50 U of EPO for several days),
often used to accelerate erythropoiesis in iron metabolism studies
[30,31,32], causes significant mobilization of storage iron from
the liver.
Figure 4. Effect of iron status on mouse liver GPI-bound
membrane hemojuvelin. Panel A: Immunoblot of supernatants from
Pi-PLC-treated samples. Panel B: Densitometric quantification of the
35 kDa Hjv band. Pi-PLC treatment was performed as described in
Materials and Methods. C: Control, Fe: Iron injection (200 mg/kg), Bl:
Bleeding (0.6 ml of blood once weekly for 3 weeks), ID: Iron-deficient diet,
Epo: Erythropoietin (50 U/day) administration for 4 days, WT: Hjv+/+ mice,
KO: Hjv2/2 mice. Arrows indicateHjv-specific bands. 60 mgofprotein was
loaded per lane, equal protein loading was verified by staining of the
membrane with Amido Black dye. Primary anti-Hjv antibody: AF3634. For
densitometry,theopticaldensityofcontrolsampleswasset at100%,n=3.
doi:10.1371/journal.pone.0037391.g004
Figure 5. Effect of iron status on mouse liver plasma mebrane
hemojuvelin. Immunoblots of hemojuvelin in samples enriched in
plasma membrane fraction. Samples were obtained with a commercial
plasma membrane extraction kit. KO: Hjv2/2 mice, C: Control, ID: Iron
deficient diet, Fe: Iron injection (200 mg/kg). Arrows indicate Hjv-
specific bands. Connexin 43 was used as loading control, 40 mgo f
protein was loaded per lane. Primary anti-Hjv antibody: AF3720.
doi:10.1371/journal.pone.0037391.g005
Figure 6. Effect of iron status on rat liver membrane
hemojuvelin. Immunoblots of Hjv protein in rat liver crude membrane
fractions. Panel A: Detection with primary anti-Hjv antibody AF3634.
Panel B: Identical samples detected with primary anti-Hjv antibody
AF3720. Panel C: Densitometric quantification of the 35 kDa Hjv band.
Liver samples from Hjv+/+ and Hjv2/2 mice are included for
comparison. C: Control; Fe: Iron injection (1200 mg/kg); ID: Iron-
deficient diet. WT: Hjv+/+ mice, KO: Hjv2/2 mice. 60 mg of protein was
loaded per lane. Arrows indicate Hjv-specific bands. Connexin 43 was
used as loading control. For densitometry, the optical density of control
samples was set at 100%, n=3.
doi:10.1371/journal.pone.0037391.g006
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The aim of the study was to determine the effect of altered iron
homeostasis on Bmp-dependent signaling, with particular empha-
sis on hepatic hemojuvelin protein levels.
Hjv is well recognized as a major component of the Bmp/Hjv
signaling pathway, which plays a crucial role in the regulation of
Hamp gene expression by iron. It has already been demonstrated
that experimental manipulation of iron levels in vivo does not
change Hjv mRNA [33]; however, there is little information about
the effect of iron overload or iron deficiency on Hjv protein levels.
In in vitro experiments with transfected cells, there was no apparent
effect of iron treatment on cellular Hjv [34,35]. On the other
hand, the recent demonstration that matriptase-2 cleaves Hjv [22]
suggests that the amount of membrane Hjv protein could be an
important determinant of hepcidin expression. In one study with a
hepatic cell line, matriptase-2 protein levels have been reported to
increase in hypoxia [25], resulting in lower Hjv levels at the
plasma membrane.
In the presented experiments, we attempted to determine the
effect of iron status on liver Hjv protein levels in whole liver
homogenates and total liver membrane fractions. Using commer-
cial anti-Hjv antibodies, and Hjv-deficient mice as negative
control, we identified two Hjv-specific bands in liver homogenates,
very probably representing two components of a membrane-
bound Hjv heterodimer. Interestingly, no apparent changes in the
intensity of these bands were observed following iron overload or
iron depletion. The same results were obtained using liver crude
membrane fraction, again demonstrating that manipulation of
iron levels does not change the total amount of membrane Hjv
protein. In addition, no changes in Hjv band intensities were
observed following iron treatment, iron depletion or erythropoietin
administration in a series of samples containing liver proteins
bound to the membrane by a GPI anchor.
Since it has been reported that plasma membrane Hjv
represents only a small fraction of total membrane Hjv [10], it
was also attempted to determine Hjv protein in samples enriched
in the plasma membrane fraction. The resulting pattern of Hjv
bands in this plasma membrane-enriched sample, obtained by a
commercial plasma membrane protein extraction kit, was similar
to the pattern obtained from crude membrane preparation, and
no apparent changes were observed following iron overload or
iron depletion.
In conclusion, using five experimental sources of Hjv protein
(mouse whole liver homogenate, crude membrane fraction, GPI
anchor-bound protein fraction, plasma membrane-enriched frac-
tion and rat liver crude membrane fraction), we were unable to
detect changes in Hjv content following iron overload or iron
depletion. These data suggest that, in vivo, dramatic changes in
hepcidin transcription can occur without noticeable changes in
hemojuvelin protein.
Although the results apparently do not support the concept that
matriptase-2 controls Hamp gene expression by modulating
membrane Hjv levels, there are important caveats to this
conclusion. First, the actual amount of plasma membrane Hjv in
contact with the Bmp6 receptor complex might be too small in
comparison with total membrane Hjv present in the crude
membrane preparation, or even in the plasma-membrane-
Table 2. Effect of experimental protocols on iron status in rats.
Treatment Hemoglobin Hematocrit MCV Liver Iron Plasma Iron
g/l % fl mg/g wet wt. mmol/l
Control 145.362.5 44.761.0 60615 5 613.0 24.762.9
Iron 145.763.1 45.362.5 5961 33406520* 62.363.7*
Control diet 140.361.3 42.060.3 59611 3 8 687 48.567.7
Low iron diet 53.065.4 16.362.1 41611 9 62* 6 . 0 63.8*
Iron was administered to male Wistar rats as iron-dextran in three weekly injections (100 mg iron/rat), total administered dose was 300 mg iron/rat. Low iron diet was
fed to female Wistar rats for four weeks after weaning. Asterisk denotes significant difference from controls (p,0.05, n=3).
doi:10.1371/journal.pone.0037391.t002
Figure 7. Determination of mouse plasma hemojuvelin by
immunoblot and ELISA. Panel A: Immunoblot of untreated mouse
plasma (80 mg of protein per lane). Panel B: Immunoblot of albumin-
depleted mouse plasma (60 mg of protein per lane). Primary anti-Hjv
antibody: AF3720. Panel C: Plasma Hjv determination by a commercial
ELISA kit. C: Control diet; ID: Iron-deficient diet; WT: Hjv+/+ mice; KO:
Hjv2/2 mice.
doi:10.1371/journal.pone.0037391.g007
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the study do not detect all Hjv fractions present in the cell,
particularly as Hjv is known to undergo complex processing
[36,37]. Nevertheless, together with our recent demonstration that
liver Hjv protein actually decreases in Tmprss62/2 mice [26], the
presented results could point to possible differences between the in
vitro and in vivo mode of action of matriptase-2, suggesting that
matriptase-2 could have other potential targets in addition to
hemojuvelin.
Theoretically, the interaction between Hjv and the Bmp6
receptor complex could be modulated by soluble Hjv [27],
possibly originating from extrahepatic tissues [34]. It was therefore
also attempted to detect an increase in plasma Hjv levels after iron
depletion. Although both antibodies reproducibly visualize Hjv-
specific bands in liver samples, Hjv-specific bands in mouse and
rat plasma or in albumin-depleted mouse plasma were not seen.
Moreover, using a recently introduced commercial mouse Hjv
ELISA kit, we did not detect any differences in plasma Hjv content
between samples obtained from Hjv+/+ and Hjv2/2 mice. Thus,
in our mouse and rat models of iron depletion, we were unable to
confirm the role of soluble Hjv in Hamp gene regulation in vivo.I t
should be noted that the release of soluble Hjv does not represent
the sole mechanism responsible for Hamp gene downregulation,
since repeated phlebotomies or erythropoietin administration
decrease liver Hamp mRNA even in Hjv2/2 mice [38].
Obviously, more research effort will be necessary to firmly
establish the tissue(s) of origin, as well as the exact physiological
role of plasma hemojuvelin.
In the presented experiments, it was attempted to manipulate
Hjv protein levels by three stimuli – by iron overload, by iron
deficiency, and also by stimulation of erythropoiesis. As expected,
both iron deficiency and EPO administration caused a dramatic
drop in Hamp mRNA. The ‘‘erythroid regulator’’ pathway, which
controls hepcidin transcription following changes in erythropoietic
activity, constitutes the least understood part of hepcidin gene
regulation [2]. Several candidates for the molecules linking
accelerated erythropoiesis in the bone marrow and spleen with
liver Hamp gene expression have been proposed [39], but their role
is probably restricted to pathological conditions such as thalasse-
mias [40]. Results from the presented experiments demonstrate
that the dramatic decrease in Hamp transcription following EPO
treatment is not mediated by changes in Hjv protein. However,
treatment with erythropoietin decreased hepatic Id1 mRNA. Id1 is
a sensitive indicator of Bmp6-dependent signaling [9], and the
decrease in Id1 mRNA after EPO treatment suggests that, under
physiological conditions, the Bmp/Hjv pathway could participate
in EPO-dependent downregulation of Hamp transcription. These
results agree with the observation made by Huang et al. [41], who
reported an EPO-mediated decrease in iron-induced levels of
phosphorylated Smad proteins. Thus, there apparently is some
cross talk between the Bmp/Hjv signaling pathway and the
erythropoiesis-regulated pathway, despite the fact that mice
lacking functional Hjv protein are still able to downregulate Hamp
mRNA following EPO administration [38]. It is worth noting that
the dose of EPO used in this and most other experiments
[30,31,32] is relatively high, and causes substantial drop in plasma
iron content, as well as a decrease in liver iron content. It is
therefore possible that the effect of EPO on hepcidin transcription,
generally attributed to some soluble circulating factor produced
during erythropoiesis [31], is in fact mainly caused by the EPO-
induced flow of iron from tissue stores and plasma to the erythroid
compartment. Further studies will be needed to clarify the role of
accelerated erythropoiesis, and particularly ineffective erythropoi-
esis, on hepcidin downregulation.
In conclusion, the presented study demonstrated that high doses
of EPO decrease liver Id1 mRNA, suggesting that accelerated
erythropoiesis influences signaling through the bone morphoge-
netic protein receptors. As main result, we consistently found
unchanged hemojuvelin protein levels following various manipu-
lations of liver iron levels. This indicates that the total amount of
hepatocyte membrane hemojuvelin is not a critical determinant of
hepatic hepcidin gene expression in vivo.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Ethics Committee
of the First Faculty of Medicine in Prague, protocol number MSM
0021620806. Phlebotomies were performed under halothane
anesthesia.
Animals and Treatment
8–10 week old male C57BL/6 mice were used for iron and
EPO administration, female C57BL/6 mice of the same age were
used for experiments with iron-deficient diet and repeated
bleeding. 0.6 ml of blood was withdrawn once weekly by
retrobulbar puncture for three weeks, and bled mice were kept
on an iron deficient diet for the duration of the experiment. For
experiments with dietary-induced iron deficiency, female mice
aged 4 weeks were fed an iron-deficient diet (Altromin GmbH,
Lage, Germany) for the next four weeks, or, in studies concerning
plasma Hjv, for eight weeks. Iron was administered as iron
polyisomaltosate (Ferrum Lek, Lek Ljubljana, Slovenia) at
200 mg/kg by intraperitoneal injection and mice were sacrificed
one week later. EPO (NeoRecormonH, Roche) was administered
once daily at 50 U/mouse for four days, mice were sacrificed
24 hours after last EPO administration.
Male outbred Wistar rats (250 g) were administered three doses
of iron-dextran (Sigma-Aldrich, 100 mg iron/week) over three
weeks, and sacrificed one week later. Female Wistar rats
(approximately 50 g) were placed on an iron deficient diet for
four weeks immediately after weaning, body weight at the time of
sacrifice was approximately 160 g.
Male Hjv2/2 mice, age 3–4 months, were a generous gift from
Prof. Silvia Arber, Basel, Switzerland [11]. Real-time PCR of
tissue cDNA samples from Hjv2/2 mice confirmed absence of
Hjv cDNA corresponding to coding exon 2 mRNA in liver, muscle
and myocardium [11], while cDNA corresponding to exon 4 was
dramatically decreased (results not shown).
Immunoblotting
Anti-Hjv antibodies (AF3634 and AF3720) were purchased
from R&D Systems (Minneapolis, MN, USA), anti-Gapdh
antibody (G9545) from Sigma Aldrich, and anti-connexin 43
antibody from Cell Signaling Technology (Danvers, MA, USA).
Secondary antibodies (705-036-147 and 713-036-137) were
obtained from Jackson ImmunoResearch Europe, UK.
For Hjv protein determination in whole tissue homogenates,
tissue samples were homogenized (5610 sec) with an Ultra Turrax
homogenizer in 5 volumes of Ripa buffer (Sigma Aldrich) with a
protease inhibitor mix (Roche Diagnostics, Mannheim, Germany)
and centrifuged for 15 min at 6000 g. 80 mg of supernatant
protein was loaded on pre-cast 4–20% Tris-Glycine gel (Invitro-
gen, Carlsbad, CA, USA). For liver membrane Hjv protein
determinations, liver was homogenized in 5 volumes of 0.25 mM
sucrose, pH 7.6, containing 1 mM EDTA and protease inhibitors.
Homogenate was centrifuged for 15 min at 6000 g, and mem-
branes were obtained by ultracentrifugation at 80 000 g for
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electrophoresis under reducing conditions (2% b-mercaptoetha-
nol) on 12% polyacrylamide gels.
For phosphatidylinositol-specific phospholipase C cleavage of
the GPI anchor, liver membrane samples (4 mg of protein) were
treated with Pi-PLC (Sigma-Aldrich, 100 mU) at 37uC for 3 hours
and subsequently recentrifuged at 80 000 g for 45 min. 60 mgo f
supernatant protein was loaded per well.
Plasma membrane proteins were extracted by Plasma Mem-
brane Protein Extraction Kit (BioVision Research Products, CA,
USA); starting amount was 150 mg of mouse liver. After collection
of the total cellular membrane protein pellet, plasma membrane
proteins were purified by adding 600 ml of the Upper Phase
Solution and further separated according to the manufacturer
protocol. The plasma membrane pellet was resuspended in 40 ml
of 0.5% Triton X-100 in phosphate-buffered saline; for electro-
phoresis, 40 mg of protein was loaded per well.
Mouse and rat plasma was diluted 1:2 with b-mercaptoethanol-
containing loading buffer and loaded at 80 mg per well. For
albumin and IgG depletion of mouse plasma, Sigma ProteoPrepH
kit was used according to manufacturer instructions; 60 mgo f
depleted plasma was loaded per lane.
Proteins were blotted on a PVDF membrane, blots were
blocked with 5% skimmed milk for one hour and incubated
overnight with a solution of the primary antibody in 5% milk.
Primary antibody dilutions were 1:500 for Hjv and connexin 43,
and 1:100 000 for Gapdh. After washing, blots were incubated
with a 1:20 000 solution of the secondary antibody and proteins
were visualized by chemiluminiscence. Densitometry of the
35 kDa bands was performed on a Biorad GS 800 scanner; for
statistical analysis, the optical density of the control sample was set
as 100%.
Plasma Hjv determination by ELISA
A commercial kit (E91995Mu, Uscn Life Sciences Inc) was used
for mouse plasma Hjv determination. Heparinised blood was
collected by retrobulbar puncture, and plasma was obtained by
centifugation at 1000 g for 15 min. ELISA was performed
immediately after separation of plasma on 1:200 diluted samples.
Real-Time PCR and Iron Determinations
RNA isolation and real-time PCR was performed as described
previously [38], Actb primers were GACATGGAGAAGATC-
TGGCA (forward) and GGTCTTTACGGATGTCAACG (re-
verse); Id1 primers were CGAGGTGGTACTTGGTCTGTC
(forward) and CTGCAGGTCCCTGATGTAGTC (reverse).
Plasma iron was determined spectrophotometrically by BioLaTest
Fe 100 kit (PLIVA-Lachema Diagnostika, Brno, Czech Republic),
liver iron was determined according to Torrance and Bothwell
[42]. Blood counts were determined on Bayer Advia 60 system.
Statistics
Statistical analysis of real-time PCR results was performed using
the Mann-Whitney test, iron metabolism parameters and densi-
tometry results were analyzed by unpaired t-test.
Supporting Information
Figure S1 Hjv immunoblot in iron-overloaded and iron-
depleted Hjv2/2 mice. Male Hjv2/2 mice were subjected to
similar experimental treatments as C57BL/6 mice. WT: Hjv+/+
mice, KO: Hjv2/2 mice, C: Control, Fe: Iron injection (200 mg/
kg), Bl: Bleeding (0.6 ml of blood once weekly for 3 weeks), Epo:
Erythropoietin (50 U/day) administration for 4 days. Primary
anti-Hjv antibody: AF3720. 60 mg of protein was loaded per lane.
Connexin 43 was used as loading control. Arrows indicate Hjv-
specific bands.
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